Delivery Order SPE2DB22D1106-SPE2DB25FFET3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,646.08 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 ml), a local anesthetic pharmaceutical product. The contract, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,342.70 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). This firm fixed price contract, issued on August 15, 2025, represents a competitively awarded procurement with no set-aside designation and an ultimate completion date of August 18, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $3,235.22 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of AmerisourceBergen's pharmaceutical supply services to the federal government and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% in a 400 mg/200 mL concentration with a ceiling value of $1,529.13. This competitive, firm fixed-price delivery order was issued on August 22, 2025, with an ultimate completion date of August 25, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Ropivacaine is a local anesthetic used in medical and surgical procedures, and this...
- The Defense Logistics Agency awarded a $1,790.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). The contract, which is a non-set-aside competitive award with an ultimate completion date of July 28, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order will be fulfilled from the vendor's facility in Conshohocken,...
- This is a $2,665.10 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of 4566997560 - Ropivacaine 0.2% 400 mg/200 mL 200 mL, with a performance period running through January 22, 2025. This delivery order is placed under Amerisourcebergen's existing $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a wholly owned subsidiary of Amerisourcebergen Corporation, to provide 4556997205 - Ropivacaine 0.2% 200 mg/100 ml 100 ml pharmaceuticals. The contract award, valued at $2,695.54, has an ultimate completion date of April 27, 2022. This delivery order is issued under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp, valued up to $999,999,999.00 with a...
- This contract award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug Corp with the Defense Logistics Agency (DLA) Troop Support Medical. The IDC, valued at $999,999,999, provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The specific delivery order is for 400 mg/200 mL of the drug Ropivacaine 0.2%, totaling $3,736.40. The contract does not have a set-aside...
- This is a $1,827.78 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of 150 mg/30 ml ropivacaine 0.5% in 30 ml vials. The award is not set-aside and has an ultimate completion date of June 26, 2025. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 0.2% Ropivacaine, a local anesthetic medication, with a ceiling value of $1,608.24 and a completion date of July 18, 2025. The contract is a firm fixed price delivery order, with no set-aside designation, indicating it was competitively awarded. Amerisourcebergen Drug Corp...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFET3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Ropivacaine 0.2% in 400 mg/200 ml doses, with a contract ceiling value of $5,062.74 and an ultimate completion date of August 25, 2025. This is a firm fixed-price delivery order executed under a competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal healthcare vendor that supplies a comprehensive range of pharmaceutical products and medical supplies to military and veteran healthcare systems. This delivery order is executed as a child contract under AmerisourceBergen Drug Corp's large Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a global pharmaceutical support vehicle enabling the company to supply an extensive range of medications, specialty pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The company's federal procurement history demonstrates consistent capability to meet DLA requirements through competitive award processes, fulfilling medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 8/22/25 |